Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IgA EGFR antibodies mediate tumour killing in vivo.
Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH. Boross P, et al. Among authors: van de winkel jg. EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929. EMBO Mol Med. 2013. PMID: 23918228 Free PMC article.
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.
Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH. Boross P, et al. Among authors: van der poel ce, de haij s, van de winkel jg. Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31. Haematologica. 2011. PMID: 21880632 Free PMC article.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: van der veer ms, van de winkel jg. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Clinical Trial.
Molecular engineering to improve antibodies' anti-lymphoma activity.
Peipp M, van de Winkel JG, Valerius T. Peipp M, et al. Among authors: van de winkel jg. Best Pract Res Clin Haematol. 2011 Jun;24(2):217-29. doi: 10.1016/j.beha.2011.03.004. Epub 2011 May 7. Best Pract Res Clin Haematol. 2011. PMID: 21658620 Review.
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T. Klausz K, et al. Among authors: van de winkel jg. Cancer Sci. 2011 Oct;102(10):1761-8. doi: 10.1111/j.1349-7006.2011.02019.x. Epub 2011 Aug 4. Cancer Sci. 2011. PMID: 21718386 Free article.
Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK. Overdijk MB, et al. Among authors: van den brakel jh, van de winkel jg. J Immunol. 2011 Sep 15;187(6):3383-90. doi: 10.4049/jimmunol.1003926. Epub 2011 Aug 10. J Immunol. 2011. PMID: 21832160 Free article.
300 results